Peptide Composition and Research Properties
CJC-1295 without DAC is a growth hormone releasing hormone (GHRH) analogue peptide engineered for enhanced stability and bioactivity in laboratory research environments. This synthetic peptide features strategic amino acid substitutions at positions 2, 8, 15, and 27 compared to native GHRH(1-29), conferring improved resistance to enzymatic degradation whilst maintaining high binding affinity for GHRH receptors. Research teams investigating growth hormone signalling pathways at Stroid UK Shop can examine this peptide’s unique pharmacokinetic profile, characterised by rapid onset and shorter half-life compared to DAC-conjugated variants.
Laboratory Research Applications
Researchers utilise CJC no DAC to investigate pulsatile growth hormone release mechanisms in controlled experimental settings. This peptide demonstrates selective activation of anterior pituitary somatotrophs through GHRH receptor binding, making it valuable for studies examining growth hormone axis regulation and feedback mechanisms. Scientists studying metabolic signalling pathways can evaluate this compound’s effects on IGF-1 expression and downstream anabolic cascades in cellular and tissue models. The rapid clearance profile makes it particularly suitable for time-course studies and investigations requiring precise temporal control. Research teams exploring CJC-1295 peptide applications often combine this compound with other growth hormone secretagogues for comprehensive mechanistic studies. Advanced researchers examining SARMs interactions frequently investigate potential synergistic effects with growth hormone modulators. Studies within the broader peptides research category often examine CJC no DAC’s role in tissue remodelling and cellular regeneration processes.
Technical Specifications
| Parameter | Specification |
|---|---|
| Molecular Weight | 3367.97 g/mol |
| CAS Registry | 863288-34-0 |
| Purity Grade | Research-grade peptide |
| Peptide Length | 29 amino acids |
| Storage Requirements | Lyophilised: -20°C, reconstituted: 2-8°C |
| Manufacturer | Beligas Pharmaceuticals |
Regulatory Compliance Statement
CJC no DAC 2mg Beligas is supplied exclusively for in-vitro laboratory research applications by qualified scientific institutions and licensed research facilities. This peptide is not approved for human consumption, therapeutic use, or any application outside controlled laboratory environments. Researchers must ensure compliance with institutional protocols and applicable regulations governing peptide research compounds. All studies must be conducted under appropriate biosafety conditions with proper documentation and oversight by qualified scientific personnel.
